Status:
COMPLETED
Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)
Lead Sponsor:
AstraZeneca
Conditions:
Hypercholesterolemia
Coronary Heart Disease
Eligibility:
All Genders
18-75 years
Brief Summary
In this study the effect of the switch to rosuvastatin from another statin (fluvastatin, pravastatin, simvastatin, atorvastatin) was evaluated in high-risk patients with and without evident CHD and LD...
Eligibility Criteria
Inclusion
- High-risk patients with and without evident CHD who had LDL-C \> 3.2 mmol/l and were treated at that moment with HMG-CoA-reductase inhibitor apart from rosuvastatin.
- Patients were aged \>18 years and \<70 years (men) and \< 75 years (women).
Exclusion
- Treatment with atorvastatin 40 or 80 mg or simvastatin 80 mg
- Patients familiar with muscular pain, myopathy or liver function disorders (inclusive elevation of serum transaminases) and/or contra-indications for treatment with rosuvastatin
Key Trial Info
Start Date :
February 1 2003
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
3889 Patients enrolled
Trial Details
Trial ID
NCT00396110
Start Date
February 1 2003
Last Update
November 6 2006
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.